Main Article Content
Pregnancy-induced hypertension (PIH) is a major concern in obstetrics, posing risks to both mothers and fetuses. Elevated serum uric acid levels have emerged as a potential indicator in PIH, yet their precise impact on maternal and fetal outcomes remains elusive. This study aimed to investigate the correlation between maternal serum uric acid levels and the outcomes experienced by both the mother and the newborn in cases of pregnancy-induced hypertension. In this cross-sectional study, 50 pregnant women in their second or third trimester diagnosed with pregnancy-induced hypertension (PIH) were included, aged between 18 and 40. Those with pre-existing conditions like chronic hypertension, chronic kidney disease, or diabetes were excluded. Data collection involved recording demographic and clinical information, including age, gestational age, parity, medical history, and blood pressure measurements using a mercury sphygmomanometer. Blood and urine samples were collected for uric acid and albumin level assessments. Diagnostic criteria for preeclampsia and its severity were applied, and fetomaternal outcomes, such as gestational diabetes, preterm birth, intrauterine growth restriction (IUGR), intrauterine death, low birth weight, and Apgar scores, were evaluated. The study found that uric acid levels were significantly associated with pregnancy induced hypertension (p=0.028) and IUGR (p=0.024). No significant correlations were observed between uric acid levels and the mode of delivery, prematurity, intrauterine death, or Apgar scores. However, infants born to mothers with uric acid levels >6 gm/dl were likelier to have low birth weight (p=0.04). Monitoring uric acid levels in PIH cases may serve as a valuable tool for risk assessment and intervention planning, potentially improving maternal and neonatal health outcomes. Further research is warranted to validate these associations and elucidate the underlying mechanisms
2. Johnson RJ, Kanbay M, Kang DH, Sánchez-Lozada LG, Feig D. Uric acid: a clinically useful marker to distinguish preeclampsia from gestational hypertension. Hypertension. 2011;58(4):548-9.
3. Gherghina ME, Peride I, Tiglis M, Neagu TP, Niculae A, Checherita IA. Uric acid and oxidative stress—relationship with cardiovascular, metabolic, and renal impairment. International Journal of Molecular Sciences. 2022;23(6):3188.
4. Bainbridge SA, Roberts JM. Uric acid as a pathogenic factor in preeclampsia. Placenta. 2008;29 Suppl A(Suppl A):S67-72.
5. Roberts JM, Bodnar LM, Lain KY, Hubel CA, Markovic N, Ness RB, Powers RW. Uric acid is as important as proteinuria in identifying fetal risk in women with gestational hypertension. Hypertension. 2005;46(6):1263-9.
6. Tenório MB, Ferreira RC, Moura FA, Bueno NB, de Oliveira ACM, Goulart MOF. Cross-Talk between Oxidative Stress and Inflammation in Preeclampsia. Oxid Med Cell Longev. 2019;2019:8238727.
7. Schmella MJ, Clifton RG, Althouse AD, Roberts JM. Uric Acid Determination in Gestational Hypertension: Is it as Effective a Delineator of Risk as Proteinuria in High-Risk Women? Reprod Sci. 2015;22(10):1212-9
8. Le TM, Nguyen LH, Phan NL, Le DD, Nguyen HVQ, Truong VQ, Cao TN. Maternal serum uric acid concentration and pregnancy outcomes in women with preeclampsia/eclampsia. Int J Gynaecol Obstet. 2019;144(1):21-26.
9. Laughon SK, Catov J, Powers RW, Roberts JM, Gandley RE. First trimester uric acid and adverse pregnancy outcomes. Am J Hypertens. 2011;24(4):489-95.
10. Rasika C, Samal S, Ghose S. Association of elevated first trimester serum uric acid levels with development of GDM. Journal of Clinical and Diagnostic Research: JCDR. 2014;8(12):OC01.
11. Mammaro A, Carrara S, Cavaliere A, Ermito S, Dinatale A, Pappalardo EM, Militello M, Pedata R. Hypertensive disorders of pregnancy. J Prenat Med. 2009;3(1):1-5.
12. Liu N, Xu H, Sun Q, Yu X, Chen W, Wei H, Jiang J, Xu Y, Lu W. The role of oxidative stress in hyperuricemia and xanthine oxidoreductase (XOR) inhibitors. Oxidative Medicine and Cellular Longevity. 2021;2021:1470380.
13. Bainbridge SA, Deng JS, Roberts JM. Increased xanthine oxidase in the skin of preeclamptic women. Reprod Sci. 2009;16(5):468-78.
14. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101-6.
15. McMullan CJ, Borgi L, Fisher N, Curhan G, Forman J. Effect of Uric Acid Lowering on Renin-Angiotensin-System Activation and Ambulatory BP: A Randomized Controlled Trial. Clin J Am Soc Nephrol. 2017;12(5):807-816.
16. Sahijwani D, Desai A, Oza H, Kansara V, Ninama P, Maheshwari K, Soni C, Padhiyar B. Serum uric acid as a prognostic marker of pregnancy induced hypertension. J South Asian Fed Obstet Gynaecol. 2012;4(3):130-3.
17. Hawkins TL, Roberts JM, Mangos GJ, Davis GK, Roberts LM, Brown MA. Plasma uric acid remains a marker of poor outcome in hypertensive pregnancy: a retrospective cohort study. BJOG. 2012;119(4):484–492.
18. Gurung SD, Shrestha J, Gauchan E, Subedi A, Shrestha A, Thapa S. Correlation of Maternal Serum Uric Acid Level and Feto-maternal Outcome in Hypertensive Disorder of Pregnancy: A Prospective Study. Nepal Journal Of Medical Sciences. 2022;7(2):13-8.
19. Nair A, Savitha C. Estimation of Serum Uric Acid as an Indicator of Severity of Preeclampsia and Perinatal Outcome. J Obstet Gynaecol India. 2017;67(2):109-118.
20. Patel T., Dudhat A. Relationship of serum uric acid level to maternal and perinatal outcome in patients with hypertensive disorders of pregnancy. GMJ. 2014;69(2):45–47.
21. Kumar N, Singh AK. Maternal Serum Uric Acid as a Predictor of Severity of Hypertensive Disorders of Pregnancy: A Prospective Cohort Study. Curr Hypertens Rev. 2019;15(2):154-160.
22. Ugwuanyi RU, Chiege IM, Agwu FE, Eleje GU, Ifediorah NM. Association between serum uric acid levels and perinatal outcome in women with preeclampsia. Obstetrics and gynecology international. 2021;2021: 6611828.